Austria Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Austria Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Austria Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The Austrian pharmaceutical market, despite its small size in comparison with its EU15 partners, has one of the highest per capita expenditures globally due to its relatively small population, high burden of non-communicable diseases and ageing population. We believe pharmaceutical spending will post modest growth over the medium term as the government links growth in public healthcare expenditure with nominal GDP growth. Overall, we view the Austrian pharmaceutical and healthcare market as relatively stable and insulated from sudden downgrades.

Headline Expenditure Projections

  • Pharmaceuticals: EUR6.29bn (USD6.97bn) in 2015 to EUR6.48bn (USD6.94bn) in 2016; 3.15% in local currency terms and -0.5% in US dollar terms. Forecasts slightly decreased from the previous quarter.

  • Healthcare: EUR37.4bn (USD41.4bn) in 2015 to EUR38.9bn (USD41.6bn) in 2016; +4.1% in local currency terms and 0.4% in US dollar terms. Forecasts unchanged from the previous quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Austria 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National sources, BMI
Pharmaceutical sales, USDbn 8.100 6.970 6.940 7.360 7.950 8.570 8.860
Pharmaceutical sales, % of GDP 1.85 1.88 1.87 1.86 1.84 1.83 1.81
Pharmaceutical sales, % of health expenditure 17.1 16.8 16.7 16.6 16.5 16.4 16.4
Health spending, USDbn 47.470 41.420 41.590 44.430 48.200 52.120 53.960

Risk/Reward Index

In our Q4 2016 Pharmaceutical Risk/Reward Index (RRI) we have assigned Austria a score of 73.8, same as in the previous quarter, which means that Austria ranks third in the region and scores only below the UK and Germany. Notably, Austria holds one of the highest RRI scores globally due to the inherent rewards and low risks that arise from an ageing population, high per capita spending and stable policy environment for drugmakers operating in the country.

Latest Updates

  • According to the Austrian Pharmacists' Association in March, 31% of 1,370 pharmacies in Austria were not profitable in 2015 despite revenues rising 5.6% in total to EUR2.62bn in the same year, as margins on prescription medication continued to contract (FriedlNews).

  • In July 2016, the European Investment Bank provided EUR25mn to Valneva, French-Austrian biotech company, which develops and markets vaccines for Lyme disease, Japanese encephalitis and Zika virus among others. The company's products are based on EB66 cell like, which according to the company is more effective in vaccine production than conventional egg-based platforms or other cell lines.

  • Also in July 2016, Valneva said that it has succeeded in generating a 'highly purified inactivated vaccine candidate' against Zika virus using the same platform as the company's Japanese encephalitis vaccine which is marketed in the United States and Europe. Valneva indicated that clinical development could start in coming months depending on the outcome of the discussions with the regulatory authorities (Reuters).

BMI Economic View

Austria's economy will start growing robustly in 2016 and 2017, driven by strong consumer demand. Fixed investment is also set to pick up due to a strong housing market, and will positively contribute to GDP growth, after three years of stagnation.

BMI Political View

Green candidate Alexander Van der Bellen's presidential election victory will realign Austria with its Western European peers and Brussels' migrant policy. However, with just short of 50.0% of the vote, Austria's far right camp has established itself as a dominant political force in the country, whose popularity will continue to surge in the quarters ahead.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Austria 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Austria 2012-2020)
12
Healthcare Market Forecast
13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2012-2020)
15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2012-2020)
15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2012-2020)
15
Prescription Drug Market Forecast
16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Austria 2012-2020)
18
Patented Drug Market Forecast
19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Austria 2012-2020)
20
Generic Drug Market Forecast
21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Austria 2012-2020)
23
OTC Drug Market Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Austria 2012-2020)
25
Pharmaceutical Trade Forecast
26
Table: Pharmaceutical Trade Data And Forecasts (Austria 2014-2020)
27
Table: Pharmaceutical Trade Data And Forecasts local currency (Austria 2014-2020)
27
Industry Risk/Reward Index
28
Western Europe Risk/Reward Index
28
Austria Risk/Reward Index
34
Rewards
34
Risks
34
Regulatory Review
36
Intellectual Property Issues
38
Pricing Regime
38
Reimbursement Regime
39
Market Overview
41
Healthcare Sector
42
Table: Healthcare Resources (Austria 2010-2015)
43
Table: Healthcare Personnel (Austria 2010-2015)
43
Table: Healthcare Activity (Austria 2010-2015)
44
Research And Development
44
Clinical Trials
45
Epidemiology
46
Competitive Landscape
48
Research-Based Industry
48
Table: Multinational Market Activity
48
Pharmaceutical Distribution
50
Table: Members Of ARGE Pharmazeutika, 2011
50
Pharmaceutical Retail Sector
52
Table: Pharmacy Outlets by Type, 2005-2009
53
Table: Pharmacy Outlets by State, 2005-2009
53
Demographic Forecast
54
Table: Population Headline Indicators (Austria 1990-2025)
55
Table: Key Population Ratios (Austria 1990-2025)
55
Table: Urban/Rural Population & Life Expectancy (Austria 1990-2025)
56
Table: Population By Age Group (Austria 1990-2025)
56
Table: Population By Age Group % (Austria 1990-2025)
57
Glossary
59
Methodology
61
Pharmaceutical Expenditure Forecast Model
61
Healthcare Expenditure Forecast Model
61
Notes On Methodology
62
Risk/Reward Index Methodology
63
Index Overview
64
Table: Pharmaceutical Risk/Reward Index Indicators
64
Indicator Weightings
65

The Austria Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Austria Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Austria pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Austria, to test other views - a key input for successful budgeting and strategic business planning in the Austrian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Austrian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Austria.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.